Importantly, concomitant inactivation of RB1 and TP53 in pre-treatment adenocarcinoma strongly predicted subsequent SCLC transformation (odds ratio 131, 95% CI 19.9–859). The gene discussed is TP53; the disease is adenocarcinoma.